Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.39 |
| ▸ | GRM5 | P41594 | 6/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847187 | 1.00 | REN (0.39) | RENGRM5AKR1C3AKR1C2ALOX5AP | |
| SCHEMBL3567660 | 0.87 | GPR119 (0.40) | RENGRM5LMNATP53 | |
| SCHEMBL3567665 | 0.87 | GPR119 (0.40) | RENGRM5LMNATP53 | |
| SCHEMBL13631084 | 0.87 | GPR119 (0.40) | RENGRM5LMNATP53 | |
| SCHEMBL3884784 | 0.87 | GPR119 (0.40) | RENGRM5LMNATP53 | |
| SCHEMBL3567662 | 0.87 | GPR119 (0.40) | RENGRM5LMNATP53 | |
| SCHEMBL4746368 | 0.84 | REN (0.44) | RENGRM5AKR1C3AKR1C2ALOX5AP | |
| SCHEMBL2849335 | 0.84 | REN (0.46) | RENGRM5AKR1C3AKR1C2ALOX5AP | |
| SCHEMBL4746364 | 0.84 | REN (0.44) | RENGRM5AKR1C3AKR1C2ALOX5AP | |
| SCHEMBL2849337 | 0.84 | REN (0.46) | RENGRM5AKR1C3AKR1C2ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130471-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130471-A1 | Renin Inhibitors | ACE, REN, DNPEP | REN 2/4885GRM5 1565/4885AKR1C3 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.